Advances in IBD Precision Medicine With Therapeutic Drug Monitoring
Gain expert insights on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for IBD and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic.
Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.
Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC